Vivus reiterated at outperform by RBC

RBC Capital Markets analyst Ken Trbovich reiterated Vivus Inc. at outperform, speculative risk, with a $6 price target on news that the company's Alista failed to provide a statistically significant benefit compared to a placebo in the treatment of women with female sexual arousal disorder in a large phase 2b trial. Vivus' earlier announcement of a late-stage obesity program of the drug Onexa provides a significant buffer to this news. Impediments to the analyst's price target include lack of timely partnerships for Avanafil and Testosterone MDTS. Shares of the Mountain View, Calif.-based pharmaceutical company were up 6 cents, or 1.62%, at $3.76. (Nasdaq: VVUS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.